Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04452669 · ClinicalTrials.gov registry record · Phase 2
VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation
A Phase 2 study, sponsored by Aerogen Pharma Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT04452669 is a Phase 2 study that has completed, run by Aerogen Pharma Limited. The registered enrollment target is 11 participants.
The verdict
NCT04452669, a Phase 2 study, has completed, sponsored by Aerogen Pharma Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate whether inhaled epoprostenol given via a breath actuated delivery system will help improve oxygen levels and treatment outcomes in patients with COVID-19 who are on mechanical ventilation.
Interventions
- DRUG VentaProst (inhaled epoprostenol delivered via a dedicated delivery system)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2020-09-15 |
| Est. Completion | 2021-06-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04452669
The ClinicalTrials.gov registry entry for NCT04452669 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aerogen Pharma Limited, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VentaProst (inhaled epoprostenol delivered via a dedicated delivery system) is the first listed.
NCT04452669 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04452669 about?
NCT04452669 is a clinical study titled "VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation". The purpose of this study is to investigate whether inhaled epoprostenol given via a breath actuated delivery system will help improve oxygen levels and treatment outcomes in patients with COVID-19 who are on mechanical ventilation.
What is the current status of trial NCT04452669?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2020-09-15. Estimated completion is 2021-06-29.
What interventions are being tested in trial NCT04452669?
The interventions under investigation include: VentaProst (inhaled epoprostenol delivered via a dedicated delivery system) (DRUG).
Who is sponsoring clinical trial NCT04452669?
This trial is sponsored by Aerogen Pharma Limited, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.